Clinical Trials List
2011-12-01 - 2014-12-31
Phase III
Terminated9
ICD-10C25.3
Malignant neoplasm of pancreatic duct
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9157.3
Malignant neoplasm of pancreatic duct
-
Trial Applicant
PharmaEngine Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Yee Chao Division of Hematology & Oncology
- Rheun-Chuan Lee Division of Radiology
- Ming-Huang Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Li-Yuan Bai Division of Hematology & Oncology
- Yu-Min Liao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 姜乃榕 Division of Hematology & Oncology
- Yan-Shen Shan Division of General Surgery
- Chia-Jui Yen Division of Hematology & Oncology
- Hui-Jen Tsai Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Nai-Jung Chiang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wen-Chi Shen Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- 曾振輝 Division of Radiology
- Po-Jung Su Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Chi-Ting Liau Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 高偉堯 Division of Hematology & Oncology
- 戴明燊 Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
- 何景良 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- Tsu-Yi Chao Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
405 participants
